A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.

ABSTRACT:

Objective

To evaluate the efficacy of a single dose of intravenous zoledronate for the treatment of HIV-associated osteopenia and osteoporosis.

Design

A double-blinded, randomized, placebo-controlled, 12-month trial of 5 mg intravenous zoledronate dose to treat 30 HIV-infected men and women with osteopenia and osteoporosis.

Methods

Following zoledronate or placebo infusions, participants were followed for 12 months on daily calcium and vitamin D supplements. Lumbar spine and hip bone density was assessed at baseline, 6 and 12 months. Biomarkers of bone metabolism were measured at baseline, 2 weeks, 3, 6, 9, and 12 months. Student's t-test and repeated measure analyses were used to evaluate bone density and bone marker changes over time.

Results

In the 30 HIV-in

SUBMITTER: Huang J 

PROVIDER: S-EPMC3477869 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature